← Back to Search

Diagnostic Imaging Techniques for Shoulder Osteoarthritis (UESOA Trial)

Q: Are participants still being accepted for this experiment?

As stated on clinicaltrials.gov, this medical research endeavour is no longer looking for participants; the initial post was made June 23rd 2021 and it had its most recent update April 19th 2022. Although not recruiting right now, there are 616 other studies that have open enrolment at present.

Q: Is the recruitment process for this clinical trial restricted to any age range, including seniors?

According to the entry requirements of this medical trial, those aged 18 - 59 are allowed to enroll.

Q: Who meets the criteria for taking part in this experiment?

Applicants for participation in this clinical trial should be between 18 and 59 years old, presenting with degenerative polyarthritis. Up to 60 candidates will be accepted into the study.

N/A

Waitlist Available

Led By Peter Lapner, MD, FRCSC

Research Sponsored by Ottawa Hospital Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults <60 years of age

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5-years post-allocation

Awards & highlights

UESOA Trial Summary

This trial is investigating the development of shoulder OA.

Who is the study for?

This trial is for adults under 60 with shoulder osteoarthritis, specifically those showing more than 55% posterior humeral head subluxation on imaging. It's not suitable for individuals over 60, those with labral or rotator cuff issues, pre-existing joint deformities beyond grade I, neurological disorders of the upper limb, history of shoulder instability or trauma including fractures.Check my eligibility

What is being tested?

The study aims to understand the causes and progression of shoulder osteoarthritis by using low-dose CT scans, T1Rho MRI imaging techniques and motion analysis to observe changes in the joint over time.See study design

What are the potential side effects?

While this study involves diagnostic tests rather than treatments, potential side effects may include discomfort during motion analysis and exposure to radiation from CT scans. The MRI procedure is generally safe but may cause claustrophobia or discomfort.

UESOA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am younger than 60 years old.

UESOA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5-years post-allocation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5-years post-allocation

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-years post-allocation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Finite Element Analysis

Motion Analysis

Magnetic Resonance Imaging

+1 more

UESOA Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group 1: Early Degeneration ('Disease')Experimental Treatment3 Interventions

Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.

Group II: Group 2: No Degeneration ('Healthy')Active Control3 Interventions

Those who have posterior subluxation of the humeral head and show no signs of degeneration.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Low-dose CT

2015

N/A

~60

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor

561 Previous Clinical Trials

2,785,631 Total Patients Enrolled

University of OttawaOTHER

206 Previous Clinical Trials

266,081 Total Patients Enrolled

Peter Lapner, MD, FRCSCPrincipal InvestigatorThe Ottawa Hospital Research Institute

Media Library

Motion Analysis Clinical Trial Eligibility Overview. Trial Name: NCT04634773 — N/A

Shoulder Osteoarthritis Research Study Groups: Group 1: Early Degeneration ('Disease'), Group 2: No Degeneration ('Healthy')

Shoulder Osteoarthritis Clinical Trial 2023: Motion Analysis Highlights & Side Effects. Trial Name: NCT04634773 — N/A

Motion Analysis 2023 Treatment Timeline for Medical Study. Trial Name: NCT04634773 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants still being accepted for this experiment?

"As stated on clinicaltrials.gov, this medical research endeavour is no longer looking for participants; the initial post was made June 23rd 2021 and it had its most recent update April 19th 2022. Although not recruiting right now, there are 616 other studies that have open enrolment at present."

Answered by AI

Is the recruitment process for this clinical trial restricted to any age range, including seniors?

"According to the entry requirements of this medical trial, those aged 18 - 59 are allowed to enroll."

Answered by AI

Who meets the criteria for taking part in this experiment?

"Applicants for participation in this clinical trial should be between 18 and 59 years old, presenting with degenerative polyarthritis. Up to 60 candidates will be accepted into the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Unravelling the Etiology of Shoulder Osteoarthritis

2021. "Unravelling the Etiology of Shoulder Osteoarthritis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04634773.